Compare Bristol-Myers Squibb Co (BMY) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Xcel Energy Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.49 (market cap $116.30B), while Xcel Energy Inc trades at $79.35 (market cap $50.05B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.3× Xcel Energy Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | XEL | |
|---|---|---|
Market Cap | $116.30B | $50.05B |
Sector | Health | Utilities |
52-Week High | $62.37 | $83.91 |
52-Week Low | $42.60 | $68.33 |
Enterprise Value | $152.24B | $87.49B |
Dividend Yield | 4.42% | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
XEL trades at $80.48, up 0.52% today, with a bullish technical signal and strong analyst consensus. Recent earnings show a Q1 2026 beat, while Q3 and Q4 2025 missed expectations. The company's $60 billion capital plan through 2030 aims to capitalize on rising electricity demand, supporting projected EPS growth. Cash flow trends show improving net cash flow, reaching $637 million in 2026. The stock is near its 52-week high, with a consensus price target of $91.88 implying potential upside.
Outlook is positive due to robust capital investment and sector tailwinds, but regulatory pushback and high valuation pose risks. Analyst sentiment is predominantly bullish, with 63% buy ratings. Investors should weigh growth prospects against execution risks and current premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
